AI Adoption Stalls: 68% of Enterprises Stuck in Early Stages
By ThePip Desk
A Teradata report reveals 68% of global enterprises are still experimenting with AI, indicating slow real-world impact. NYSE also noted Alzheimer’s trial updates.
🔥 Main Takeaway
A new Teradata report indicates most companies are still in the early stages of AI adoption, hinting that the widespread impact of artificial intelligence might be further off than current market hype suggests.
📌 What Happened?
The NYSE Content Update on July 7, 2026, highlighted a significant report from Teradata, which revealed that a substantial 68% of global enterprises are currently in the ‘Experimenting’ or ‘Developing’ phases of AI implementation. According to Teradata CIO Josh Fecteau, a mere 7% of these businesses have managed to achieve tangible outcomes from their AI initiatives so far.
Separately, Annovis Bio announced a major milestone, reaching full enrollment of 850 patients for its Phase 3 trial of Buntanetap, a promising treatment for early Alzheimer’s Disease. Meanwhile, IBM celebrated the launch of its new Compact z17 and LinuxONE Systems, and Goldman Sachs Asset Management marked anniversaries for several of its funds, including the one-year for GBND and GIGL, and ten-year for GSLC.
💰 Why It Matters
This slow pace of AI adoption, with most companies still experimenting, signals a significant gap between AI’s potential and its practical enterprise execution. For investors, this suggests that the promised productivity boosts from AI might take longer to materialize, potentially impacting valuations of tech stocks heavily reliant on AI growth narratives.
Annovis Bio’s full enrollment in its Alzheimer’s trial is a critical step forward, potentially bringing a new treatment closer to market. This development could represent a major opportunity for biotech investors and offer significant hope for patients and families affected by the disease.
👀 What to Watch Next
Keep an eye on upcoming AI-focused events like the MACHINA Summit and the RAISE Summit in Paris, as these platforms often reveal new trends and innovations in the artificial intelligence space. These discussions could offer clarity on how enterprises plan to accelerate beyond the current ‘experimenting’ phase.
Investors should closely monitor the results from Annovis Bio’s Phase 3 trial for Buntanetap. Positive data could significantly impact the company’s stock performance and reshape the landscape of Alzheimer’s treatments. Additionally, observe how companies like IBM continue to evolve their foundational hardware, which is essential for scaling AI infrastructure.